Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users - 17/08/11
, Thomas Kerr a, Anita Palepu b, Ruth Zhang a, Steffanie A. Strathdee c, Mark W. Tyndall a, Julio S.G. Montaner a, b, Robert S. Hogg a, c
Corresponding author. Address: BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Tel.: +1 604 806 9116; fax: +1 604 806 9044.Summary |
Objectives |
We examined the time to antiretroviral therapy (ART) use among antiretroviral naïve HIV infected injection drug users participating in a prospective cohort study in Vancouver, Canada.
Methods |
Time to the initiation of ART was evaluated using Kaplan–Meier methods and Cox proportional hazards regression. The cohort was stratified based on Aboriginal and non-Aboriginal (primarily Caucasian) ethnicity.
Results |
Between May 1996 and May 2003, 312 HIV-infected individuals were enrolled into the cohort. At 24 months after enrolment, the rate of ART use was 29.2% among Aboriginal participants and was 53.7% among non-Aboriginal participants (log-rank P=0.023), and lower uptake of ART persisted in multivariate analyses (relative hazard=0.37 [95% CI: 0.15–0.93]; P=0.035).
Conclusions |
These findings demonstrate lower uptake of HIV/AIDS care among Aboriginal injection drug users and demonstrate the need for interventions to improve access to HIV care among indigenous populations.
Le texte complet de cet article est disponible en PDF.Keywords : Injection drug use, HIV, AIDS, Antiretroviral therapy, Aboriginal
Plan
Vol 52 - N° 4
P. 233-236 - avril 2006 Retour au numéro
Article précédent
- Prevalence of hepatitis C virus infection in children admitted to an urban hospital
- Patrick Gerner, Stefan Wirth, Philip Wintermeyer, Alexander Walz, Andreas Jenke
- Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir
- Myrto Astriti, Valérie Zeller, David Boutolleau, Agnès Gautheret-Dejean, George Allen, Danielle Seilhean, Henri Agut, François Bricaire, Christine Katlama, Philippe Bossi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?